|
rs1042522
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In conclusion, genetic variants in <i>TP53</i> were found in all TNBC tumors, with rs1042522 being the most frequent (94% of TNBC biopsies), which had not been previously reported in TNBC.
|
30867801 |
2019 |
|
rs13000023
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Additionally, rs4849887 was significantly associated with overall BC risk, and both rs2363956 and rs13000023 were associated with TNBC-specific risk, although none as strongly as the Duffy-null variant.
|
31356281 |
2019 |
|
rs141366047
|
|
|
0.010 |
GeneticVariation |
BEFREE |
To assess the context-dependent roles, we carried out MDM2 and MDMX knockdown in orthotopic tumors of TNBC MDA-MB-231 cells expressing mtp53 R280K and MDM2 knockdown in ERα<sup>+</sup> T47D cells expressing mtp53 L194F.
|
30642351 |
2019 |
|
rs148047459
|
|
|
0.010 |
GeneticVariation |
BEFREE |
To assess the context-dependent roles, we carried out MDM2 and MDMX knockdown in orthotopic tumors of TNBC MDA-MB-231 cells expressing mtp53 R280K and MDM2 knockdown in ERα<sup>+</sup> T47D cells expressing mtp53 L194F.
|
30642351 |
2019 |
|
rs2491231
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The rs2491231 variant in the <i>FLT3</i> gene was identified in 84% (16/19) of the samples, which not yet reported for TNBC, to the best of our knowledge.
|
30867801 |
2019 |
|
rs2814778
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Frequency of the Duffy-null allele (rs2814778; an African ancestral variant adopted under selective pressure as protection against malaria) was associated with TNBC-specific risk (P < 0.0001), quantified West African Ancestry (P < 0.0001) and was more common in AA, Ghanaians, and TNBC cases.
|
31356281 |
2019 |
|
rs40239
|
|
|
0.010 |
GeneticVariation |
BEFREE |
<b>Conclusion:</b> Our case-control study suggests that MET T1010I seems to be a risk factor for TNBC in the Caucasian Greek population, in contrast with MET rs40239, where no correlation was found.
|
31213837 |
2019 |
|
rs4849887
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Additionally, rs4849887 was significantly associated with overall BC risk, and both rs2363956 and rs13000023 were associated with TNBC-specific risk, although none as strongly as the Duffy-null variant.
|
31356281 |
2019 |
|
rs4938723
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Prognostic significance of miR-34 rs4938723 T > C polymorphism in triple negative breast cancer patients.
|
30935968 |
2019 |
|
rs56391007
|
|
|
0.010 |
GeneticVariation |
BEFREE |
<b>Conclusion:</b> Our case-control study suggests that MET T1010I seems to be a risk factor for TNBC in the Caucasian Greek population, in contrast with MET rs40239, where no correlation was found.
|
31213837 |
2019 |
|
rs769772228
|
|
|
0.010 |
GeneticVariation |
BEFREE |
To assess the context-dependent roles, we carried out MDM2 and MDMX knockdown in orthotopic tumors of TNBC MDA-MB-231 cells expressing mtp53 R280K and MDM2 knockdown in ERα<sup>+</sup> T47D cells expressing mtp53 L194F.
|
30642351 |
2019 |
|
rs11615
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our findings firstly show that the T allele of ERCC1 rs11615 can serve as a predictive biomarker for breast cancer and TNBC.
|
30096175 |
2018 |
|
rs12075
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our study suggested that rs12075 could be served as a key predictive factor of recurrence risk in breast cancer, especially for TNBC subtype.
|
30358125 |
2018 |
|
rs121913016
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Whole exome sequencing in triple negative breast cancer cases (n = 8) and targeted sequencing in healthy controls (n = 48) revealed BRIP1 rs552752779 (MAF: 75% vs. 6.25%, OR 45.00, 95% CI 9.43-243.32), ERBB2 rs527779103 (MAF: 62.5% vs. 7.29%, OR 21.19, 95% CI 5.11-94.32), ERCC2 rs121913016 (MAF: 56.25% vs. 7.29%, OR 16.34, 95% CI 4.02-70.41), MSH6 rs2020912 (MAF: 56.25% vs. 1.04%, OR 122.13, 95% CI 12.29-2985.48) as risk factors for triple negative breast cancer.
|
30136158 |
2018 |
|
rs1235679626
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Collectively, these findings provide the first functional evidence for the M276I mutation in promoting TNBC progression.
|
30093560 |
2018 |
|
rs1360485
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In addition, the presence of one G allele in SNPs rs1360485 or rs2249825 was associated with a higher risk of progressing to T2 tumor and distant metastasis amongst HER2-enriched and triple-negative breast cancer (TNBC) tumors compared with luminal A and luminal B tumors.
|
29725248 |
2018 |
|
rs1412125
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Furthermore, having one C allele in the rs1412125 domain increased the risk of pathologic grade 3 disease in HER2-enriched and TNBC tumors.
|
29725248 |
2018 |
|
rs142030651
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A point mutation in the adenoviral E1A binding protein p300 (EP300-G211S) was significantly correlated to this TNBC subgroup.
|
30132219 |
2018 |
|
rs1651654
|
|
|
0.010 |
GeneticVariation |
BEFREE |
As shown in this analysis, rs1651654 and exm585172 SNPs are found to be determinants of TNBC risk.
|
28918577 |
2018 |
|
rs1801157
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The present study analyzed genetic polymorphisms in CXCL12 (rs1801157, G > A) and CXCR4 (rs2228014, C > T) and CXCR4 immunostaining in tumor tissues from patients with triple negative breast cancer (TNBC) aiming to evaluate their possible role in its' susceptibility and prognosis.
|
29926386 |
2018 |
|
rs200928781
|
|
|
0.010 |
GeneticVariation |
BEFREE |
CONCLUSIONS Our findings indicated that CHEK2 Y390C mutation induced the drug resistance of TNBC cells to chemotherapeutic drugs through administrating cell apoptosis and cell cycle arrest via regulating p53 activation and CHEK2-p53 apoptosis pathway.
|
29761796 |
2018 |
|
rs2020912
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Whole exome sequencing in triple negative breast cancer cases (n = 8) and targeted sequencing in healthy controls (n = 48) revealed BRIP1 rs552752779 (MAF: 75% vs. 6.25%, OR 45.00, 95% CI 9.43-243.32), ERBB2 rs527779103 (MAF: 62.5% vs. 7.29%, OR 21.19, 95% CI 5.11-94.32), ERCC2 rs121913016 (MAF: 56.25% vs. 7.29%, OR 16.34, 95% CI 4.02-70.41), MSH6 rs2020912 (MAF: 56.25% vs. 1.04%, OR 122.13, 95% CI 12.29-2985.48) as risk factors for triple negative breast cancer.
|
30136158 |
2018 |
|
rs2228014
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The present study analyzed genetic polymorphisms in CXCL12 (rs1801157, G > A) and CXCR4 (rs2228014, C > T) and CXCR4 immunostaining in tumor tissues from patients with triple negative breast cancer (TNBC) aiming to evaluate their possible role in its' susceptibility and prognosis.
|
29926386 |
2018 |
|
rs2249825
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In addition, the presence of one G allele in SNPs rs1360485 or rs2249825 was associated with a higher risk of progressing to T2 tumor and distant metastasis amongst HER2-enriched and triple-negative breast cancer (TNBC) tumors compared with luminal A and luminal B tumors.
|
29725248 |
2018 |
|
rs3212986
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The rs11615 and rs3212986 of ERCC1 were investigated and evaluated for their associations with susceptibility to breast cancer, especially TNBC, in Taiwan.
|
30096175 |
2018 |